PI3K inhib 
Welcome,         Profile    Billing    Logout  
 67 Companies  59 Products   59 Products   344 Diseases   342 Trials   12240 News 


«12...111112113114115116117118119120121...229230»
  • ||||||||||  Journal:  EEF1D Promotes Glioma Proliferation, Migration, and Invasion through EMT and PI3K/Akt Pathway. (Pubmed Central) -  Apr 30, 2021   
    Furthermore, knockdown of EEF1D could reduce cell proliferation and impaired epithelial-mesenchymal transition (EMT) phenotypes, including cell invasion. Taken together, these results indicate that EEF1D and its partner proteins might play a critical role in glioma and serve as a potential therapeutic target of glioma.
  • ||||||||||  irbesartan / Generic mfg.
    Preclinical, Journal:  Yiqi Jiedu Huayu Decoction Alleviates Renal Injury in Rats With Diabetic Nephropathy by Promoting Autophagy. (Pubmed Central) -  Apr 30, 2021   
    Sprague-Dawley rats were randomly divided into a normal control group, a diabetic group, an irbesartan group, and three groups receiving different doses of YJHD...In conclusion, our study shows that YJHD further inhibits the mTOR pathway and promotes autophagy by regulating the activity of the PI3K/Akt and AMPK pathways, thereby improving podocyte injury, protecting renal function, and reducing renal fibrosis. This study provides support for the application of and further research into YJHD.
  • ||||||||||  [VIRTUAL] ME06 - PI 3-Kinase and Cancer Metabolism (Channel 02) -  Apr 29, 2021 - Abstract #AACR2021AACR_6110;    
    This same enzyme mediates insulin responses in liver, muscle, fat and other tissues and drugs that inhibit this enzyme have the expected effect of raising serum glucose and insulin levels. Data will be presented showing that dietary and pharmaceutical interventions that limit elevation of serum insulin improve responses to PI3K inhibitors in mouse models of cancer by preventing insulin-dependent activation of PI3K in tumors.
  • ||||||||||  quercetin (LY294002) / Eli Lilly
    Journal, PARP Biomarker, IO biomarker:  Pristimerin-induced uveal melanoma cell death via inhibiting PI3K/Akt/FoxO3a signalling pathway. (Pubmed Central) -  Apr 29, 2021   
    Taken together, present results showed that Pristimerin induced apoptotic cell death through inhibition of PI3K/Akt/FoxO3a pathway in UM-1 cells. These findings indicate that Pristimerin may be considered as a potential chemotherapeutic agent for patients with UM.
  • ||||||||||  Aliqopa (copanlisib) / Bayer
    Preclinical, Journal:  Preclinical activity of PI3K inhibitor Copanlisib in Gastrointestinal Stromal Tumor. (Pubmed Central) -  Apr 29, 2021   
    In conclusion, copanlisib has single-agent anti-tumor activity in GIST regardless KIT mutational status or sensitivity to imatinib. Effective KIT inhibition is necessary in order to achieve synergistic or additive effects with the combination of imatinib and any given PI3K/mTOR pathway inhibition.
  • ||||||||||  Journal:  Speedy/RINGO protein interacts with ERK/MAPK and PI3K/AKT pathways in SH-SY5Y neuroblastoma cells. (Pubmed Central) -  Apr 29, 2021   
    This study provides information about a possible interaction of Speedy/RINGO with PI3K/AKT and ERK/MAPK pathways in SH-SY5Y cells for the first time. It will not only help to better understand the cancer-prone interactions of these pathways but also enable us to identify the appropriate molecular targets for developing efficient treatment strategies.
  • ||||||||||  Journal:  ARHGAP20 Expression Inhibited HCC Progression by Regulating the PI3K-AKT Signaling Pathway. (Pubmed Central) -  Apr 29, 2021   
    Furthermore, we revealed that downregulated ARHGAP20 was significantly correlated with larger tumor size and vascular invasion, and could be used as an adverse independent prognostic factor for HCC OS but not RFS. ARHGAP20 was identified for the first time as a tumor suppressor gene that could inhibit HCC progression by regulating the PI3K-AKT signaling pathway and the immune microenvironment in HCC.
  • ||||||||||  Zeneo Sumatriptan (sumatriptan needle-free injection) / Crossject
    Journal:  Gi-coupled receptor activation potentiates Piezo2 currents via Gβγ. (Pubmed Central) -  Apr 28, 2021   
    Local injection of sumatriptan, an agonist of the Gi-coupled serotonin 1B/1D receptors, increases mechanical sensitivity in mice, and the effect is abolished by inhibiting PI3K and MAPK. Hence, our studies illustrate an indirect mechanism of action of Gβγ to sensitize Piezo2 currents and alter mechanosensitivity after activation of Gi-coupled receptors.
  • ||||||||||  quercetin (LY294002) / Eli Lilly
    Journal, IO biomarker:  ROS accumulation contributes to abamectin-induced apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway in TM3 Leydig cells. (Pubmed Central) -  Apr 28, 2021   
    Pretreatment with a PI3K/AKT inhibitor, LY294002, mimicked the ABA-mediated effects on cytotoxicity...However, N-acetylcysteine as ROS scavengers inhibited ABA-induced apoptosis and autophagy and reversed these ABA-mediated effects on PI3K/AKT/mTOR pathway. On the basis of the above results, it is suggested that ABA exposure induces apoptosis and autophagy in TM3 cells by ROS accumulation to mediate PI3K/AKT/mTOR signaling pathway suppression.
  • ||||||||||  Journal:  Exosome-transferred LINC01559 promotes the progression of gastric cancer via PI3K/AKT signaling pathway. (Pubmed Central) -  Apr 28, 2021   
    Of note, LINC01559 targeted both PGK1 and PTEN to promote GC progression by activating PI3K/AKT pathway. Taken together, our study demonstrated that LINC01559 accelerated GC progression via upregulating PGK1 and downregulating PTEN to trigger phosphatidylinositol 3-kinase/AKT serine/threonine kinase (PI3K/AKT) pathway, indicating LINC01559 as a potential biomarker for GC treatment.
  • ||||||||||  Zydelig (idelalisib) / Gilead
    Clinical, Journal:  Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma. (Pubmed Central) -  Apr 28, 2021   
    Additionally, previously untreated patients were at higher risk of developing a severe AE compared to previously treated patients (HR 3.19, 95% CI 1.48, 6.84; p = .003). These results caution against the use of untested PI3K inhibitor combinations in routine practice and suggest that early phase clinical trials should utilize conservative treatment schemas.
  • ||||||||||  Journal:  Leukemia cells remodel marrow adipocytes via TRPV4-dependent lipolysis. (Pubmed Central) -  Apr 28, 2021   
    In addition, an AML mouse model exhibited smaller BM adipocytes, whereas the TRPV4 activator 4α-phorbol 12,13-didecanoate (4αPDD) partly rescued this process and increased survival. In conclusion, TRPV4 plays a critical role in BM adipocyte remodeling induced by leukemia cells, suggesting that targeting TRPV4 may constitute a novel strategy for AML therapy.
  • ||||||||||  Journal:  The role of PI3K inhibitors in the treatment of malignant lymphomas. (Pubmed Central) -  Apr 28, 2021   
    Future research might identify effective combinatorial therapy approaches for PI3K inhibitors to further improve response rates. This review discusses the most recent developments in the field of PI3K inhibition in different subtypes of lymphoma.